東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Cost-utility analysis of medications...

Pistoresi, Ryan.

FindBook

Google Book

Amazon

博客來

Cost-utility analysis of medications for relapsing-remitting multiple sclerosis: A United States third-party payer perspective.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Cost-utility analysis of medications for relapsing-remitting multiple sclerosis: A United States third-party payer perspective./
作者:	Pistoresi, Ryan.
面頁冊數:	36 p.
附註:	Source: Masters Abstracts International, Volume: 55-01.
Contained By:	Masters Abstracts International55-01(E).
標題:	Pharmaceutical sciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1600453
ISBN:	9781339090238

Cost-utility analysis of medications for relapsing-remitting multiple sclerosis: A United States third-party payer perspective.
Pistoresi, Ryan.

Cost-utility analysis of medications for relapsing-remitting multiple sclerosis: A United States third-party payer perspective. - 36 p.

Source: Masters Abstracts International, Volume: 55-01.

Thesis (M.S.)--University of Washington, 2015.

Background: Many new disease-modifying therapies (DMTs) have recently been approved for relapsing-remitting multiple sclerosis (RRMS) in the United States. Objective: To assess the values of 10 first-line therapies for RRMS, including generic glatiramer acetate, versus the natural history of disease for a newly diagnosed RRMS patient. Perspective: United States third-party payer. Methods: A Markov model was developed and estimates were made using data on natural history of disease progression, annual relapse rates, medication efficacy, costs, and utilities to determine incremental cost-effectiveness ratios (ICERs). Results: Base case is a cohort of 30-year-old females at Extended Disability Status Scale (EDSS) state 0 at a 20 year time horizon versus the natural history of disease. Dimethyl fumarate demonstrates the lowest ICER at $895,073/QALY. Conclusions: DMTs for RRMS have low value versus the natural history of disease, and would not be considered cost-effective by conventional standards.

ISBN: 9781339090238Subjects--Topical Terms:

3173021
Pharmaceutical sciences.

Cost-utility analysis of medications for relapsing-remitting multiple sclerosis: A United States third-party payer perspective.
LDR:01933nmm a2200289 4500 001 2070930
005 20160628072926.5
008 170521s2015 ||||||||||||||||| ||eng d
020 $a 9781339090238
035 $a (MiAaPQ)AAI1600453
035 $a AAI1600453
040 $a MiAaPQ $c MiAaPQ
100 1 $a Pistoresi, Ryan. $3 3186016
245 1 0 $a Cost-utility analysis of medications for relapsing-remitting multiple sclerosis: A United States third-party payer perspective.
300 $a 36 p.
500 $a Source: Masters Abstracts International, Volume: 55-01.
500 $a Adviser: Louis P. Garrison.
502 $a Thesis (M.S.)--University of Washington, 2015.
520 $a Background: Many new disease-modifying therapies (DMTs) have recently been approved for relapsing-remitting multiple sclerosis (RRMS) in the United States. Objective: To assess the values of 10 first-line therapies for RRMS, including generic glatiramer acetate, versus the natural history of disease for a newly diagnosed RRMS patient. Perspective: United States third-party payer. Methods: A Markov model was developed and estimates were made using data on natural history of disease progression, annual relapse rates, medication efficacy, costs, and utilities to determine incremental cost-effectiveness ratios (ICERs). Results: Base case is a cohort of 30-year-old females at Extended Disability Status Scale (EDSS) state 0 at a 20 year time horizon versus the natural history of disease. Dimethyl fumarate demonstrates the lowest ICER at $895,073/QALY. Conclusions: DMTs for RRMS have low value versus the natural history of disease, and would not be considered cost-effective by conventional standards.
590 $a School code: 0250.
650 4 $a Pharmaceutical sciences. $3 3173021
650 4 $a Economics. $3 517137
650 4 $a Health care management. $3 2122906
690 $a 0572
690 $a 0501
690 $a 0769
710 2 $a University of Washington. $b Pharmacy. $3 3186017
773 0 $t Masters Abstracts International $g 55-01(E).
790 $a 0250
791 $a M.S.
792 $a 2015
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1600453